Search results
Results from the WOW.Com Content Network
Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Eli Lilly’s experimental insulin that is injected just once a week is as effective as daily insulin injections for maintaining blood sugar levels in patients with type 1 or type 2 diabetes ...
Common names of these medications include semaglutide (Ozempic and Wegovy), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity). [36] These medications must be injected and are usually injected in the upper arm, thighs or stomach areas. [37] They are usually given once a week but some of the medication can be as frequent as twice daily ...
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood.With the exception of insulin, most GLP-1 receptor agonists (liraglutide, exenatide, and others), and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as effective as daily insulin shots for managing A1C levels in diabetes. Experts ...
By Sriparna Roy and Mariam Sunny (Reuters) -Advisers to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of ...
Insulin glargine/lixisenatide, sold under the brand name Soliqua among others, is a fixed-dose combination medication that combines insulin glargine and lixisenatide and is used to treat diabetes. The most common side effects include hypoglycemia (low blood glucose), diarrhea, vomiting and nausea (feeling sick).
(Reuters) -Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice ...